Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tighter Levothyroxine Standards Are Only First Step To Higher Quality – Cmte.

Executive Summary

Tightening levothyroxine potency standards will not address underlying concerns about the quality of the manufacturing process for such products, members of the Endocrinologic & Metabolic Drugs and Pharmaceutical Science Advisory Committees said

You may also be interested in...



FDA narrows levothyroxine potency specs

Levothyroxine sodium potency specifications are tightening in response to concerns that the drug's potency may deteriorate prior to its expiration date. Currently allowed up to 10 percent potency degradation over the course of the product's shelf life, the thyroid treatment will now be required to meet a 95 percent to 105 percent potency specification until the expiration date, consistent with the recommendations of a joint FDA advisory committee. Presented with FDA's analysis of stability data supplied by manufacturers, the Endocrinologic & Metabolic Drugs and Pharmaceutical Science Advisory Committees overwhelmingly recommended that potency specifications should be narrowed (1"The Pink Sheet" Oct. 9, 2006, p. 16). Manufacturers will have two years to comply with the specifications, according to FDA...

FDA narrows levothyroxine potency specs

Levothyroxine sodium potency specifications are tightening in response to concerns that the drug's potency may deteriorate prior to its expiration date. Currently allowed up to 10 percent potency degradation over the course of the product's shelf life, the thyroid treatment will now be required to meet a 95 percent to 105 percent potency specification until the expiration date, consistent with the recommendations of a joint FDA advisory committee. Presented with FDA's analysis of stability data supplied by manufacturers, the Endocrinologic & Metabolic Drugs and Pharmaceutical Science Advisory Committees overwhelmingly recommended that potency specifications should be narrowed (1"The Pink Sheet" Oct. 9, 2006, p. 16). Manufacturers will have two years to comply with the specifications, according to FDA...

Levothyroxine Bioequivalence Standards Will Remain, FDA Tells Workshop

FDA will not alter its bioequivalence standards for levothyroxine products despite concerns from three thyroid and endocrine medical societies, the agency said at a May 23 public meeting held in Washington, D.C

Related Content

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel